AZ-1355 is a potent hypolipidemic agent that inhibits platelet aggregation in vivo and increases the prostaglandin I2/thromboxane A2 ratio in vitro; it significantly reduces serum triglycerides (TG) and total cholesterol (TC) in rats, lowers hepatic TC and TG levels in rats fed different diets, and reproducibly decreases serum total cholesterol in Triton-induced hyperlipidemic mice.